UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 19, 2015

 

NUTRACEUTICAL INTERNATIONAL CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware
(State of incorporation)

 

000-23731
(Commission
File Number)

 

87-0515089
(IRS Employer
Identification No.)

 

1400 Kearns Boulevard, 2nd Floor
Park City, Utah

 

84060

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (435) 655-6106

 

Not Applicable
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 2.02 Results of Operations and Financial Condition.

 

On November 19, 2015, Nutraceutical International Corporation (“Nutraceutical”) reported results for the fiscal 2015 fourth quarter and year ended September 30, 2015.  The press release reporting the results is attached to this Form 8-K as Exhibit 99.1.

 

The press release referenced in this Item 2.02, to the extent that it discusses financial results of Nutraceutical for the quarter and year ended September 30, 2015, is being furnished pursuant to this Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

Nutraceutical herewith files the following documents as exhibits to this Current Report on Form 8-K:

 

(d)   Exhibits

 

Exhibit
Number

 

Description

 

 

 

99.1

 

Press release issued by Nutraceutical dated November 19, 2015

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

NUTRACEUTICAL INTERNATIONAL CORPORATION

 

(Registrant)

 

 

 

By:

/s/ Cory J. McQueen

Date: November 19, 2015

 

 

 

 

Cory J. McQueen

 

 

Vice President and Chief Financial Officer

 

 

(Principal Financial and Accounting Officer)

 

3



 

EXHIBIT INDEX

 

Exhibit
Number

 

Description

99.1

 

Press release issued by Nutraceutical dated November 19, 2015

 

4




Exhibit 99.1

 

FOR:

NUTRACEUTICAL INTERNATIONAL CORPORATION

 

 

CONTACT:

Cory McQueen

 

Vice President and

 

Chief Financial Officer

 

(435) 655-6106

 

NUTRACEUTICAL REPORTS FISCAL 2015 YEAR END RESULTS

 

PARK CITY, Utah, Nov 19, 2015/PRNewswire/—Nutraceutical International Corporation (NASDAQ:  NUTR) today reported results for the fiscal 2015 fourth quarter ended September 30, 2015.  Net sales for the fiscal 2015 fourth quarter were $53.6 million, compared to $52.4 million for the same quarter of fiscal 2014.  For the fourth quarter of fiscal 2015, net income was $3.4 million, or $0.35 diluted earnings per share, compared to net income of $3.4 million, or $0.35 diluted earnings per share, for the same quarter of fiscal 2014.

 

Net sales for the fiscal year ended September 30, 2015 were $216.5 million, compared to $214.5 million for fiscal 2014.  For the fiscal year ended September 30, 2015, net income was $15.3 million, or $1.59 diluted earnings per share, compared to net income of $15.9 million, or $1.62 diluted earnings per share, for fiscal 2014.

 

In September 2015, the Company decided to implement an expanded brand consolidation plan in an effort to simplify its brand offerings, which should make marketing and sales activities more efficient and facilitate customer ordering.  As part of this plan, the Company determined, as of September 30, 2015, its indefinite-lived tradenames should be assigned finite useful lives.  In connection with this change and the Company’s annual impairment test, non-cash intangible asset impairment charges were recorded totaling $1.8 million ($1.1 million, net of tax, or $0.12 per diluted share), which are included in net income for the fourth quarter and fiscal year ended September 30, 2015.  Net income for the fourth quarter and fiscal year ended September 30, 2014  also included a non-cash intangible asset intangible asset impairment charge related to a tradename of $0.3 million ($0.2 million, net of tax, or $0.02 per diluted share).

 

Operating cash flow for the fiscal year ended September 30, 2015 was $25.0 million, compared to $20.0 million for fiscal 2014.  The operating cash flow for the fiscal year ended September 30, 2015, combined with existing cash, was primarily used to repay net borrowings of $11.5 million on the Company’s revolving credit facility and to invest $8.6 million in purchases

 



 

of property, plant and equipment, $5.3 million in purchases of common stock for treasury and $1.3 million in acquisitions of natural product businesses.

 

Bill Gay, chairman and chief executive officer, commented, “Our fiscal 2015 fourth quarter showed solid improvements in net sales and Adjusted EBITDA.  Acquisitions completed in the last two fiscal years contributed to the net sales growth for fiscal 2015.  International net sales rebounded in the fourth quarter, although for the full fiscal year they still were $1.8 million less than fiscal 2014.  Operational synergies, cost reductions and automation had a positive impact in the fourth quarter.”

 

Mr. Gay stated, “Net income for the fourth quarter and fiscal year were slightly down primarily due to the $1.8 million non-cash expense relating to our expanded brand consolidation plan.  The consolidation of brands should provide for marketing and operational efficiencies.  Operating cash flows in fiscal 2015 enabled stock repurchases, debt reductions and investments in property and acquisitions for future growth.”

 

Mr. Gay continued, “In October 2015, we completed the acquisition of Dynamic Health, a liquid manufacturing business in Brooklyn, New York.  This acquisition expands our product offering of organic and nutritional juice concentrates. Dynamic Health’s 100 plus branded products are primarily sold through health food distributors and internet accounts.  Dynamic Health also sells private label products to domestic and international customers.  We are targeting integration of the Dynamic Health business into our Tulsa, Oklahoma manufacturing facility over the next 12-15 months. Dynamic Health’s net sales, which we anticipate will be over $15 million annually, should positively contribute to Adjusted EBITDA during fiscal 2016.”

 

According to Mr. Gay, “Management is committed to finding additional operational efficiencies in all areas of the company during fiscal 2016, including raw materials, labor and overhead. Management would like to thank our employees and stakeholders for their ongoing support of our long-term business strategy.”

 

ABOUT NUTRACEUTICAL

 

We are an integrated manufacturer, marketer, distributor and retailer of branded nutritional supplements and other natural products sold primarily to and through domestic health and natural food stores.  Internationally, we market and distribute branded nutritional supplements and other

 



 

natural products to and through health and natural product distributors and retailers.  Our core business strategy is to acquire, integrate and operate businesses in the natural products industry that manufacture, market and distribute branded nutritional supplements.  We believe that the consolidation and integration of these acquired businesses provide ongoing financial synergies through increased scale and market penetration, as well as strengthened customer relationships.

 

We manufacture and sell nutritional supplements and other natural products under numerous brands, including Solaray®, KAL®, Nature’s Life®, LifeTime®, Natural Balance®, NaturalCare®, Health from the Sun®, Pioneer®, Nutra BioGenesis™, Life-flo®, Organix South®, Heritage Store® and Monarch Nutraceuticals™.

 

We own neighborhood natural food markets, which operate under the trade names The Real Food Company™, Thom’s Natural Foods™, Cornucopia Community Market™ and Granola’s™.  We also own health food stores, which operate under various trade names, including Fresh Vitamins™ and Peachtree Natural Foods®.

 

We manufacture and/or distribute one of the broadest branded product lines in the industry, with approximately 7,500 SKUs, including approximately 750 SKUs exclusively sold internationally.  We believe that, as a result of our emphasis on innovation, quality, loyalty, education and customer service, our brands are widely recognized in health and natural food stores and among their customers.

 

This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to our financial condition, results of operations and business. These forward-looking statements can be identified by the use of terms such as “believe,” “expects,” “plan,” “intend,” “may,” “will,” “should,” “can,” or “anticipates,” or the negative thereof, or variations thereon, or comparable terminology, or by discussions of strategy. These statements involve known and unknown risks, uncertainties and other factors that may cause industry trends or our actual results to be materially different from any future results expressed or implied by these statements.  Important factors that may cause our results to differ from these forward-looking statements include, but are not limited to: (i) changes in or new government regulations or increased enforcement of the same including adverse determinations by regulators; (ii) unavailability of desirable acquisitions, inability to complete them or inability to integrate them; (iii) increased costs, including from increased raw material or energy prices; (iv) changes in general worldwide economic or political conditions; (v) adverse publicity or negative consumer perception regarding nutritional supplements; (vi) issues with obtaining raw materials of adequate quality or quantity; (vii) litigation and claims, including product liability, intellectual property and other types;  (viii) disruptions from or following acquisitions including the loss of customers; (ix) increased competition; (x) slow or negative growth in the nutritional supplement industry or the healthy foods channel; (xi) the loss of key personnel or the inability to manage our operations efficiently; (xii) problems with information management systems, manufacturing efficiencies and operations, including system interruptions and security/cybersecurity breaches; (xiii) insurance coverage issues; (xiv) the volatility of the stock market generally and of our stock specifically; (xv) increases in the cost of borrowings or unavailability of additional debt or equity capital, or both, or fluctuations in foreign currencies; and (xvi) interruption of business or negative impact on sales and earnings due to acts of God, acts of war, terrorism, bio-terrorism, civil unrest and other factors outside of our control.  Copies of our SEC reports are available upon request from our investor relations department or may be obtained at the SEC’s website (www.sec.gov).

 

# # #

 



 

NUTRACEUTICAL INTERNATIONAL CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited; dollars in thousands)

 

 

 

September 30,

 

September 30,

 

 

 

2015

 

2014

 

Assets

 

 

 

 

 

Current assets, net

 

$

86,215

 

$

83,850

 

Property, plant and equipment, net

 

77,645

 

79,244

 

Goodwill

 

24,384

 

23,622

 

Other non-current assets, net

 

24,205

 

28,062

 

 

 

$

212,449

 

$

214,778

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

Current liabilities

 

$

20,528

 

$

21,709

 

Long-term liabilities

 

31,674

 

43,456

 

Stockholders’ equity

 

160,247

 

149,613

 

 

 

$

212,449

 

$

214,778

 

 



 

NUTRACEUTICAL INTERNATIONAL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited; dollars in thousands, except per share data)

 

 

 

Three months ended September 30,

 

Twelve months ended September 30,

 

 

 

2015

 

2014

 

2015

 

2014

 

Net sales

 

$

53,649

 

$

52,440

 

$

216,479

 

$

214,474

 

Cost of sales

 

26,962

 

26,509

 

110,255

 

108,169

 

Gross profit

 

26,687

 

25,931

 

106,224

 

106,305

 

Operating expenses

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

18,852

 

19,249

 

77,256

 

76,874

 

Amortization of intangible assets

 

680

 

727

 

2,869

 

2,667

 

Impairment of intangible assets

 

1,810

 

267

 

1,810

 

267

 

Income from operations

 

5,345

 

5,688

 

24,289

 

26,497

 

Interest and other expense, net

 

224

 

397

 

1,051

 

1,421

 

Income before provision for income taxes

 

5,121

 

5,291

 

23,238

 

25,076

 

Provision for income taxes

 

1,747

 

1,858

 

7,967

 

9,187

 

 

 

 

 

 

 

 

 

 

 

Net income

 

$

3,374

 

$

3,433

 

$

15,271

 

$

15,889

 

 

 

 

 

 

 

 

 

 

 

Net income per common share

 

 

 

 

 

 

 

 

 

Basic

 

$

0.35

 

$

0.35

 

$

1.59

 

$

1.62

 

Diluted

 

0.35

 

0.35

 

1.59

 

1.62

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding

 

 

 

 

 

 

 

 

 

Basic

 

9,519,598

 

9,690,673

 

9,588,838

 

9,792,276

 

Diluted

 

9,520,425

 

9,698,438

 

9,592,734

 

9,801,080

 

 



 

NUTRACEUTICAL INTERNATIONAL CORPORATION

ADJUSTED EBITDA SCHEDULE

(unaudited; dollars in thousands)

 

 

 

Three months ended September 30,

 

Twelve months ended September 30,

 

 

 

2015

 

2014

 

2015

 

2014

 

 

 

 

 

 

 

 

 

 

 

Net income

 

$

3,374

 

$

3,433

 

$

15,271

 

$

15,889

 

Provision for income taxes

 

1,747

 

1,858

 

7,967

 

9,187

 

Interest and other expense, net (1)

 

224

 

397

 

1,051

 

1,421

 

Depreciation and amortization

 

3,063

 

3,111

 

12,765

 

11,468

 

Impairment of intangible assets (2)

 

1,810

 

267

 

1,810

 

267

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA

 

$

10,218

 

$

9,066

 

$

38,864

 

$

38,232

 

 


(1)         Includes amortization of deferred financing fees.

 

(2)         Non-cash intangible asset impairment charges of $1,810 related to certain tradenames were recorded for the three months and twelve months ended September 30, 2015. A non-cash intangible asset impairment charge of $267 related to a tradename was recorded for the three months and twelve months ended September 30, 2014.

 

Non-GAAP Financial Measures

 

Adjusted EBITDA (a non-GAAP measure) is defined in our performance measures as earnings before net interest and other expense, taxes, depreciation, amortization and goodwill and intangible asset impairments.  We believe that Adjusted EBITDA provides useful additional information to analysts, creditors, investment bankers and management regarding operating performance and debt covenant compliance.  Adjusted EBITDA has some inherent limitations in measuring operating performance due to the exclusion of certain financial elements such as depreciation and amortization and is not necessarily comparable to other similarly-titled captions of other companies due to potential inconsistencies in the method of calculation.  Furthermore, Adjusted EBITDA is not intended to be an alternative to net income in determining our operating performance in accordance with generally accepted accounting principles.

 


Nutraceutical International Corp. (MM) (NASDAQ:NUTR)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Nutraceutical International Corp. (MM) Charts.
Nutraceutical International Corp. (MM) (NASDAQ:NUTR)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Nutraceutical International Corp. (MM) Charts.